What was Apollo Hospitals’ net profit in Q3 FY25–26?
- Answer Field
-
Apollo Hospitals reported a consolidated net profit of ₹502 crore in Q3 FY25–26.
Apollo Hospitals Enterprise Limited reported consolidated revenue of ₹6,477 crore in Q3 FY25–26, registering year-on-year growth. Net profit stood at ₹502 crore, driven by hospital expansion, improved operating leverage, and traction in digital health and pharmacy distribution.
Apollo Hospitals Enterprise Limited announced its unaudited consolidated financial results for the quarter ended December 31, 2025 (Q3 FY25–26).
For the quarter, revenue from operations stood at ₹6,477 crore, while net profit came in at ₹502 crore. Performance was supported by growth in healthcare services, improved margins, capacity expansion, and continued momentum in Apollo HealthCo’s digital and pharmacy platform.
Apollo Hospitals Enterprise Limited declared its unaudited Q3 FY25–26 financial results on 10 February 2026. The results cover the company’s performance for the quarter ended December 31, 2025, and were approved by the Board of Directors following a limited review by the statutory auditors.
All figures in ₹ crore | Unaudited
Particulars | Q3 FY25–26 | Q2 FY25–26 | Q3 FY24–25 | QoQ Change (%) | YoY Change (%) |
Revenue from operations | ₹6,477.40 | ₹6,303.50 | ₹5,526.90 | 2.75% | 17.20% |
Other income | ₹52.80 | ₹54.70 | ₹63.80 | (3.47%) | (17.24%) |
Total income | ₹6,530.20 | ₹6,358.20 | ₹5,590.70 | 2.71% | 16.81% |
Total expenses | ₹5,843.90 | ₹5,689.80 | ₹5,059.80 | 2.71% | 15.49% |
Profit before tax | ₹682.00 | ₹674.70 | ₹536.20 | 1.08% | 27.20% |
Net profit (PAT) | ₹516.30 | ₹494.00 | ₹379.40 | 4.51% | 36.07% |
EPS – Basic (₹) | ₹34.94 | ₹33.19 | ₹25.89 | 5.27% | 34.97% |
EPS – Diluted (₹) | ₹34.94 | ₹33.19 | ₹25.89 | 5.27% | 34.97% |
All figures in ₹ crore | Unaudited
Particulars | Q3 FY25–26 | Q2 FY25–26 | QoQ Change (%) |
Revenue from operations | ₹6,477.40 | ₹6,303.50 | 2.75% |
Total income | ₹6,530.20 | ₹6,358.20 | 2.71% |
Total expenses | ₹5,843.90 | ₹5,689.80 | 2.71% |
Net profit (PAT) | ₹516.30 | ₹494.00 | 4.51% |
On a quarter-on-quarter basis, revenue improved moderately, while profitability strengthened sequentially due to operating leverage and better segment performance.
Apollo Hospitals operates across Healthcare Services, Retail Health & Diagnostics, and Digital Health & Pharmacy Distribution.
All figures in ₹ crore | Unaudited
Segment | Q3 FY25–26 Revenue | Q3 FY24–25 Revenue |
Healthcare Services | ₹3,225.30 | ₹2,802.90 |
Retail Health & Diagnostics | ₹466.80 | ₹389.60 |
Digital Health & Pharmacy Distribution | ₹2,827.50 | ₹2,352.40 |
Others | ₹1.30 | ₹1.20 |
Digital Health & Pharmacy Distribution remained the fastest-growing vertical, while Healthcare Services continued to contribute the largest share of revenue.
Segment Results (Consolidated)
All figures in ₹ crore | Unaudited
Particulars | Q3 FY25–26 |
Healthcare Services | ₹624.30 |
Retail Health & Diagnostics | ₹11.70 |
Digital Health & Pharmacy Distribution | ₹108.00 |
Others | ₹2.10 |
Sub-Total (Segment Results) | ₹746.10 |
Apollo Hospitals Enterprise Limited released its Q3 FY25–26 financial results post-market hours on 10 February 2026. As of 11th February 2026 at 14.30 PM IST, Apollo Hospitals Enterprise Limited shares were trading at ₹7,528.80, up 4.28% (+₹308.80) from the previous close of ₹7,220.00.
Apollo Hospitals Enterprise Limited reported consolidated revenue of ₹6,477 crore and net profit of ₹502 crore in Q3 FY25–26. Year-on-year profit growth reflects operating leverage, robust hospital performance, and sustained digital health expansion. Sequential improvement indicates steady demand and disciplined cost management, positioning the company for continued growth.
For more quarterly result updates, visit Bajaj Broking’s Quarterly Results Calendar.
No result found
Apollo Hospitals reported a consolidated net profit of ₹502 crore in Q3 FY25–26.
The company recorded consolidated revenue from operations of ₹6,477 crore during the quarter.
The results are unaudited and have undergone a limited review by statutory auditors.
The results were announced on 10 February 2026.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading